It was reported that the treatment of refractory colorectal cancer with regorafenib, an inhibitor of multiple kinases, including vascular endothelial growth factor receptor (VEGFR) 1–3, Tie2, KIT, platelet derived growth factor receptor and RET, achieved a 6% partial response and 23% stable disease. Here, TEK is linked to colorectal cancer.